Esperion Therapeutics Inc (NASDAQ:ESPR)‘s stock had its “hold” rating reiterated by equities research analysts at Royal Bank of Canada in a research report issued to clients and investors on Monday. They presently have a $45.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price suggests a potential upside of 90.11% from the company’s current price.
A number of other research analysts also recently commented on ESPR. Needham & Company LLC set a $25.00 price target on Esperion Therapeutics and gave the company a “buy” rating in a research note on Saturday, February 4th. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 2nd. Credit Suisse Group AG raised Esperion Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday. Finally, Citigroup Inc raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $14.00 to $39.00 in a research note on Tuesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Esperion Therapeutics presently has an average rating of “Buy” and a consensus target price of $29.39.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 74.65% during mid-day trading on Monday, hitting $41.34. 29,887,321 shares of the company were exchanged. The firm has a 50 day moving average of $23.80 and a 200 day moving average of $15.00. The company’s market capitalization is $932.42 million. Esperion Therapeutics has a 12-month low of $9.40 and a 12-month high of $42.59.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.24) by $0.05. During the same quarter last year, the business earned ($0.58) earnings per share. Equities research analysts forecast that Esperion Therapeutics will post ($6.04) earnings per share for the current year.
var userip;Your IP Address: document.write(userip);
Several hedge funds have recently added to or reduced their stakes in the company. Keybank National Association OH purchased a new stake in Esperion Therapeutics during the fourth quarter valued at $159,000. Elkfork Partners LLC purchased a new stake in Esperion Therapeutics during the fourth quarter valued at $169,000. Advisor Group Inc. boosted its stake in Esperion Therapeutics by 0.6% in the third quarter. Advisor Group Inc. now owns 14,437 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 85 shares during the period. Virginia Retirement Systems ET AL purchased a new stake in Esperion Therapeutics during the third quarter valued at $242,000. Finally, Dimensional Fund Advisors LP boosted its stake in Esperion Therapeutics by 54.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 40,220 shares of the biopharmaceutical company’s stock valued at $504,000 after buying an additional 14,257 shares during the period. Institutional investors own 64.65% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.